The advent of monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates targeting HER2 has markedly enhanced the therapeutic outcomes for HER2-positive breast cancer patients [5]. This evidence concerns the gene ERBB2 and breast carcinoma.